Cellyan Biotechnology
HKPD
9 hedge funds and large institutions have $78.6K invested in Cellyan Biotechnology in 2026 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, reducing their positions, and 1 closing their positions.
21,389% more capital inflows, than outflows
Capital inflows: $88.3K | Capital outflows: $411
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
50% more funds holding
Funds holding: 6 → 9 (+3)
2.55% more ownership
Funds ownership: 2.23% → 4.78% (+2.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XTX Topco
George Town,
Cayman Islands
|
+$29.1K |
| 2 |
HRT Financial
New York
|
+$18.5K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$10.4K |
| 4 |
Jane Street
New York
|
+$10.3K |
| 5 |
StoneX Group
New York
|
+$9.41K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$411 |
HKPD Hedge Fund Activity: Q3 2026 in Review
9 of the 8,220 institutional investors tracked by Wall St. Rank reported a position in Cellyan Biotechnology (HKPD) for Q3 2026, worth a combined $78.6K — down 26% from $106K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new HKPD positions and 1 closed out — a net gain of 3 holders — while 4 added to existing stakes and 0 trimmed.
The largest buyer was XTX Topco, adding an estimated $29.1K. The largest seller was UBS Group, exiting entirely with an estimated $411 sold.
- 9 institutional investors held Cellyan Biotechnology (HKPD) as of Q3 2026, up from 6 in Q2 2026.
- Funds reported $78.6K of Cellyan Biotechnology stock for Q3 2026, down 26% quarter-over-quarter.
- 4 funds opened new Cellyan Biotechnology positions in Q3 2026 and 1 closed out, a net change of +3 holders.
- The largest Cellyan Biotechnology buyer in Q3 2026 was XTX Topco, an estimated $29.1K added.
- The largest Cellyan Biotechnology seller in Q3 2026 was UBS Group, an estimated $411 sold.
Based on aggregated 13F filings for Q3 2026.